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Abstract
The endothelial glycocalyx (eGC), a carbohydrate-rich layer lining the luminal side of the endothelium, regulates
vascular adhesiveness and permeability. Although central to the pathophysiology of vascular barrier dysfunction in
sepsis, glycocalyx damage has been generally understudied, in part because of the aberrancy of in vitro preparations
and its degradation during tissue handling. The aim of this study was to analyze inflammation-induced damage of the
eGC on living endothelial cells by atomic-force microscopy (AFM) nanoindentation technique. AFM revealed the
existence of a mature eGC on the luminal endothelial surface of freshly isolated rodent aorta preparations ex vivo, as
well as on cultured human pulmonary microvascular endothelial cells (HPMEC) in vitro. AFM detected a marked
reduction in glycocalyx thickness (266 ± 12 vs. 137 ± 17 nm, P<0.0001) and stiffness (0.34 ± 0.03 vs. 0.21 ± 0.01
pN/mn, P<0.0001) in septic mice (1 mg E. coli lipopolysaccharides (LPS)/kg BW i.p.) compared to controls.
Corresponding in vitro experiments revealed that sepsis-associated mediators, such as thrombin, LPS or Tumor
Necrosis Factor-α alone were sufficient to rapidly decrease eGC thickness (-50%, all P<0.0001) and stiffness (-20%
P<0.0001) on HPMEC. In summary, AFM nanoindentation is a promising novel approach to uncover mechanisms
involved in deterioration and refurbishment of the eGC in sepsis.
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Introduction
Endothelial hyperpermeability is a hallmark of systemic
inflammatory response syndrome (SIRS) and sepsis that
largely contributes to high morbidity and mortality in critically-ill
patients. The often devastating clinical consequences of this
process are net extravasation of fluid, a profound decrease in
systemic vascular tone, and collapse of the microcirculation,
leading to distributive shock, acute lung and kidney injury [1-3].
Inflammation-induced vascular leakage has long been ascribed
to a malfunction of the endothelial cell itself. However, recent
studies provided compelling evidence that the endothelium is
protected against pathogenic insults by a highly hydrated
negatively charged “firewall” on the luminal side called the
glycocalyx [4-6]. Given its strategic location as the interface
between the blood and the endothelium, the intact glycocalyx
mediates flow-induced shear stress on endothelial cells,
prevents transvascular protein leakage and reduces leukocyte-
endothelial interactions [5,7,8].
The endothelial glycocalyx (eGC) is a carbohydrate-rich gel-
like mesh of large anionic polymers covering the luminal
surface of endothelium along the entire vascular tree. The most
prominent components of the eGC are the proteoglycans,
especially those of the syndecan family, to which both highly
sulfated glycosaminoglycans (mainly heparan- and chondroitin
sulfates) and hyaluronan are attached [9,10]. Along with
various incorporated proteins of plasmatic and endothelial
origin, the eGC attains thickness of up to 2 µm and thus is
considerably thicker than the endothelial cells themselves
[9,11-15]. Under physiological conditions, the structure of the
glycocalyx layer is fairly stable but subject to a permanent
dynamic balance between biosynthesis of new
glycosaminoglycans and shear dependent removal of existing
constituents.
Selective thinning of the eGC by enzyme digestion promotes
microvascular hyperpermeability [16-19] and exposes
previously hidden endothelial surface adhesion molecules
including ICAM-1 and VCAM-1, allowing neutrophil recognition
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of, and adhesion to, the endothelial surface [5,20]. It has been
shown that loss of the eGC constituents - and as a
consequence softening of the eGC - can lead to changes in
microvascular rheology and haemodynamics [21,22].
Observational studies in critically ill patients with sepsis
indicate that plasma levels of shed glycocalyx constituents
correlate with disease severity and mortality [23-25].
However, despite its fundamental role in regulating vascular
integrity and functions central to the pathophysiology of sepsis,
there is a lack of methods to visualize and quantify glycocalyx
deterioration in vitro. The atomic force microscope (AFM)
fascilitates quantitative analysis of nanomechanical properties
of living cells [26-28]. In a recent proof-of-principle study, we
successfully employed AFM nanoindentation to disclose the
eGC on split-open arteries from a human umbilical cord [29].
Here, we aimed to employ this novel methodology to analyze
sepsis-induced (nano-) mechanical changes of the eGC ex vivo
and in vitro for the first time.
Materials and Methods
In vivo animal studies
All procedures were approved by a governmental committee
on animal welfare (Landesamt für Natur, Umwelt und
Verbraucherschutz Nordrhein-Westfalen), performed according
to international animal protection guidelines and all efforts were
made to minimize suffering. Eight to fourteen week-old male
Lewis-Brown Norway rats (weighing 250–380 g) and eight-
week-old male C57BL/6 mice (weighing 20–25 g) were
obtained from Janvier (Janvier, Le Genest Saint Isle, France)
and Charles River (The Charles River Laboratories; Sulzfeld,
Germany). All animals had free access to standard chow and
tap water, and were acclimated to the facility for at least one
week before beginning an experiment.
Enzymatic degradation of the endothelial glycocalyx in
rats.  Rats were anesthetized with ketamine 100 mg/kg body
weight (BW) intraperitoneal (i.p.) and xylazine 5 mg/kg BW i.p.
(CEVA Tiergesundheit, Düsseldorf, Germany). Enzymatic
degradation of the endothelial glycocalyx in vivo was induced
by infusing heparinase I (140 Sigma-Units/kg BW; Sigma, St.
Louis, MO, USA) via the tail vein. An equal amount of solvent
(0.9% NaCl) served as control. Aortas (n = 5 per group) were
harvested 45 min after injection of heparinase or solvent.
Endotoxemia in mice.  Mice were intraperitoneally injected
with 1 mg/kg BW lipopolysaccharide (LPS) from Escherichia
coli, serotype O111:B4 (Sigma-Aldrich, St. Louis, MO). An
equal amount of solvent (phosphate-buffered saline - PBS)
served as control. Aortas (n = 4 per group) were harvested 18
h after administration of LPS or solvent.
Tissue harvest and preparation.  Harvest and preparation
of aortas for ex vivo analysis by AFM is visualized in Figure 1.
Aortas were perfused with PBS (PAA Laboratories, Pasching,
Austria) with 1% Penicillin and Streptomycin (Biochrom AG,
Berlin, Germany) via cardiac puncture, isolated, immediately
bathed in PBS with 1% Penicillin/Streptomycin (Pen/Strep) and
freed from surrounding tissue. Small patches (~4 mm2) of the
whole aorta were attached on Cell-Tak® (BD Biosciences,
Bedford, MA, USA) coated glass, with the endothelial surface
facing upwards. After preparation, the patches were bathed in
minimal essential medium (MEM; Invitrogen Corp., La Jolla,
CA, USA) supplemented with 20% fetal calf serum (FCS; PAA
Laboratories, Pasching, Austria), 1% MEM vitamins
(Invitrogen), 1% MEM nonessential amino acids (Invitrogen)
and 1% Pen/Strep.
Experimental conditions
Indentation measurements on aorta preparations or cultured
endothelial cells (see below) were performed before and after
enzymatic degradation by various doses (see below) of
heparinase I, hyaluronidase, or chondroitinase (all Sigma) for
60 min at 37°C unless stated otherwise. In addition, indentation
measurements on cultured endothelial cells were performed
before and after challenge with the following sepsis mediators
for 60 min at 37°C: a) thrombin (1 U/ml, Sigma), b) E. coli LPS
(100 ng/ml, Sigma) plus LPS-binding protein (100 ng/ml,
Sigma) plus CD14 (10 ng/ml, Sigma) or c) Tumor Necrosis
Factor (TNF)-α (10 ng/ml, Peprotech, Hamburg, Germany)
dissolved in sterile water (Braun AG, Melsungen, Germany).
Immunofluorescence Microscopy
After preparation, aortic patches were fixed for 15 minutes in
4% paraformaldehyde (30% Formaldehyde, Carl ROTH GmbH,
Karlsruhe, Germany) at 4°C. Following fixation, samples were
permeabilized for 5 min in 0.1 % Triton X-100 (Carl ROTH
GmbH, Karlsruhe, Germany) at 4°C, blocked with 10% normal
goat serum (Sigma, St. Louis, MO, USA) for 30 minutes, and
incubated for 1 hour with the primary antibody (polyclonal
rabbit anti-human CD31 (PECAM) antibody, Abbiotec, San
Diego, CA, USA). After serial washes in PBS, the samples
were incubated with the Fluorophore-conjugated secondary
antibody (goat anti-rabbit Alexa Fluoro 488, Invitrogen
Molecular Probes, Eugene, Oregon, USA) for 60 minutes.
Coverslips were mounted with Dako Fluorescent Mounting
Medium (Dako, Via Real, Carpinteria, USA). Images were
taken with a ZEISS Axio Observer (Zeiss, Jena, Germany)
using the Meta Morph software version 7.5.6.0 (Molecular
Devices, Biberach an der Risse, Germany).
Electron Microscopy
For electron microscopy rats were anaesthetized and
perfused with a solution composed of 2% glutaraldehyde, 2%
sucrose, 0.1 M sodium cacodylate buffer (pH 7.3), and 2%
lanthanum nitrate through a cannula placed in the left ventricle.
Thereafter, the aorta was harvested diced. Three to four pieces
of approximately 1 mm3 each were immersed in the fixation
solution for 2 h and remained overnight in a solution without
glutaraldehyde before being washed in alkaline (0.03 mol/l
NaOH) saccharose (2%) solution. After contrast enhancement
with a solution containing 2% osmium tetroxide and 2%
lanthanum nitrate, embedding in araldite, and microtomic
sectioning, electron microscopy of the eGC was performed as
previously described [4].
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Atomic force microscopy
Thickness and stiffness of the eGC were determined using
the Atomic Force Microscope (AFM) nanoindentation
technique. Preservation of the endothelial cell layer on aorta
preparations was approved by immunostaining of PECAM-1/
CD31 (Figure 1). Figure 2 A, B illustrates the basic principles of
this method. By using a Multimode AFM (Veeco, Mannheim,
Germany) with a feedback-controlled heating device (Veeco)
measurements were performed at 37°C as described
previously [29].
In brief, the central component of the AFM is a very sensitive
mechanical nanosensor – a triangular cantilever with a
mounted spherical tip (here: electrically uncharged polystyrene,
diameter = 10 µm, Novascan, Ames, IA, USA) that is utilized to
periodically indent the cells. A spherical tip was used for this
AFM approach instead of a sharp tip because of a larger
interaction area between tip and sample that decreases the
effective pressure and results in less mechanical noise [30].
The cantilever functions as a soft spring (spring constant = 11
pN/nm). The xyz-position of the tip is precisely controlled by a
piezo-element (Figure 2 A). A laser beam is reflected by the
gold-coated backside of the cantilever to a position-sensitive
quadrupled photodiode allowing measurements of the
cantilever deflection (V). Determination of the spring constant
Figure 1.  Preparation of rat aorta for AFM analysis ex vivo.  (A-C) Aorta was isolated, freed from surrounding tissue and cut in
rings. The aortic rings were split into small preparations (approximately 4 mm2). For atomic force microscopy (AFM) analysis aorta
preparations were attached on glass coverslips with the endothelial surface facing upwards. (D) Preservation of the endothelial cell
layer after preparation was approved by immunofluorescence staining for CD31 (PECAM-1).
doi: 10.1371/journal.pone.0080905.g001
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Figure 2.  Setup of the atomic force microscope (AFM) used in this study (A) for nanomechanical analysis of the
endothelial glycocalyx (eGC) and an original tracing of a force indentation curve performed on the endothelial surface of a
rat aorta (B) ex vivo.  1) The AFM tip travels vertically towards the endothelial surface. 2) Upon indentation of the endothelial
glycocalyx (eGC), the AFM cantilever, which serves as a soft spring, is deflected. The cantilever deflection is measured as a laser
beam reflected from the back of the cantilever and is plotted as a function of sample position along the z axis. The resulting curve is
transformed into a force-versus-indentation curve using the cantilever’s spring constant and the optical lever sensitivity. The slope of
a force indentation curve then directly reflects the stiffness (expressed in pN/nm), which is necessary to indent the eGC for a certain
distance. The first slope indicates the stiffness (in this trace 0.38 pN/nm) of the very first layer, the endothelial glycocalyx (eGC). The
second slope indicates the stiffness of the plasma membrane and the cortical actin web. Practically, the slope of a force indentation
curve is deduced from a manually plotted regression line (similar to the line in the trace) in PUNIAS (Protein Unfolding and Nano-
Indentation Analysis Software, Version 1.0, Release 1.8, http:// punias.voila.net/). In our experience, this slope is virtually linear over
its entire length, resulting in a single fixed stiffness value. The distance between the starting point of eGC indentation and the
starting point of the second slope (projected to the x-axis) corresponds to the thickness of the eGC (in this trace 422.6 nm).
doi: 10.1371/journal.pone.0080905.g002
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(Kcant) by the thermal tuning method and measurement of the
deflection sensitivity (α) of the cantilever on bare glass
coverslips facilitate the calculation of the force (F) acting on the
cantilever and, in turn, the force exerted by the cantilever to the
sample.
F=V ·α ·Kcant
Since the piezo displacement (xpiezo) and the deflection
sensitivity (α) are known, the indentation depth (deformation) of
the sample (xsample) can be calculated.
xsample= xpiezo− α ·V
For reasons of readability the indentation depth is hereafter
called “thickness”. It should be noted that the indentation depth
rather represents an apparent thickness, rather than the exact
anatomical thickness.
Force indentation curves of a single cell were obtained by
plotting the force (F) necessary to indent the cell (indentation
depth, xsample). The sample stiffness can be derived from Hook
´s law.
Ksample= Fxsample
The stiffness (K) is the mechanical resistance of a sample
against a defined deformation (e.g. indentation). K depends
strongly on the indentation depth and the location, because
cells contain a variety of substructures and organelles. The
experimental parameters including an indentation velocity of 1
µm/s, a loading force of approximately 400 pN, an indentation
frequency in the range of 0.25 - 0.5 Hz, a ramp size of 2 µm, a
trig threshold of 35 nm and a tip velocity of 0.5 - 1 µm/s.
Previous experiments, using 1 µm AFM-tips, showed that the
glycocalyx thickness is somewhat variable [29,31]. Since we
were interested in the overall condition of the glycocalyx and
especially in its changes induced by different stimuli, we here
chose larger tips (10 µm), as they indent a larger area. Thus
they provided “more averaged” results and enabled us to avoid
the data being influenced by the spatial distribution of the eGC
thickness. All measurements were performed in HEPES-
buffered solution [standard composition in millimolars: 140
NaCl, 5 KCl, 1 MgCl2, 1 CaCl2, 5 Glucose, 10 HEPES (N-2-
hydroxyethylpiperazine-N′-2-ethanesulfonic acid), pH 7.4]
supplemented with 1% FCS in order to prevent eGC collapse
[32].
Light microscopy was used to ensure that the tip position of
the mechanical nanosensor was located neither at the nuclear,
nor at the junctional region of cultured endothelial cells.
However, this approach was not feasible in (thick) explanted
aortas due to the lack of transparency of sub-endothelial layers
such as the Tunica media and T. externa.
Figure 3 A, B show typical force indentation curves of an
untreated as well as heparinase-treated aortic endothelial cell
(“overview mode”). Each force indentation curve was then
analyzed separately with a higher magnification (“working
mode”) by using a linear approximation for determination of the
eGC nanomechanics (Figure 3 C).
Cell culture
Primary human umbilical venous endothelial cells (HUVECs)
were isolated and grown in culture as previously described
[33]. Cells were maintained in M199 (Gibco, Karlsruhe,
Germany) supplemented with 10% heat-inactivated fetal calf
serum (FCS; PAA Laboratories, Pasching, Austria), 1% Pen/
Strep, 50 U/mL heparin (Biochrom AG) and 1% growth
supplement derived from bovine retina. Confluent HUVECs of
the first or second passage were used for experiments. The
human umbilical vein endothelial cell line EA.hy 926 [34] was
grown in Dulbecco's modified Eagle's medium (DMEM;
Invitrogen, Karlsruhe, Germany) supplemented with 1% Pen/
Strep, and 10% FCS. The human pulmonary microvascular
endothelial cell line HPMEC-ST1.6R [35] was grown in M199
medium (Gibco, Karlsruhe, Germany), supplemented with 20%
FCS, glutamax at 2 mM (Invitrogen, Darmstadt, Germany), 1%
Pen/Strep, sodium heparin at 25 mg/ml, and endothelial growth
factor supplement at 25 μg/ml (BD Biosciences, Bedford, MA,
USA). The bovine aortic endothelial cell line GM 7373 (DSMZ,
Braunschweig, Germany) was grown in minimal essential
medium (MEM; Invitrogen) supplemented with 20% FCS, 1%
MEM vitamins, 1% MEM nonessential amino acids and 1%
Pen/Strep as described [29]. The murine brain microvascular
endothelial cell line bEnd.5 [36] was cultured in DMEM
supplemented with 10% FCS, 1% L-glutamine (Biochrom AG,
Berlin, Germany), 1% non-essential amino acids, 100 mM
sodium-pyruvate (Fisher Scientific), 25 mM β-
Mercaptoenthanol (Sigma, St. Loius, MO, USA) and 1% Pen/
Strep. All cells were cultivated in T25 culture flasks. For AFM
analysis, cells were grown for 6 days on glass coverslips
[bEnd.5 cells were cultured on glass coverslips coated with
0.5% gelatine (Sigma–Aldrich Chemie GmbH, Steinheim,
Germany), EA.hy926 and HPMEC-ST1.6R were grown on
fibronectin-coated glass coverslips (Roche Diagnostics GmbH,
Mannheim, Germany)] at 37°C and 5% CO2.
Statistical analysis
Data are presented as absolute value with mean, or mean
with standard error of the mean (SEM). Differences between
two groups were analyzed by Student’s t-test. Differences
between ≥ 3 groups were analyzed by using the one-way
analysis of variance (ANOVA) with Bonferroni’s multiple
comparison test. All tests were two-sided and significance was
accepted at P<0.05. GraphPad Prism Version 5.02 (GraphPad
Prism Software Inc, San Diego, California, USA) was used for
data analysis and figure preparation.
Results
Nanomechanical changes of the eGC after enzymatic
degradation
A reductionist approach used by many groups, including
ours, is to elucidate the roles and functions of different eGC
constituents using enzyme digestions. Initially, we used freshly-
isolated aortic preparations from untreated rats to mimic
physiological conditions as closely as possible. Similar to
previous investigations [28,31,37,38] two different slopes could
be identified depending on the indentation depth of the
Glycocalyx in Sepsis
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cantilever. The first slope (indentation depth of the first hundred
nanometers) represents the stiffness of the eGC, whereas the
second steep slope reflects the stiffness of the plasma
membrane with the underlying cortical actin web (cell cortex)
(Figure 2 B). Time-course and dose-response experiments
showed that within 60 minutes after addition of heparinase I (1
Sigma-Unit/mL), which cleaves heparan sulfate residues,
glycocalyx thickness and stiffness decreased by a maximum of
approximately 50% (from 308 ± 68 nm to 154 ± 26 nm,
P<0.0001) and 33% (from 0.34 ± 0.05 pN/nm to 0.23 ± 0.01
pN/nm, P<0.0001), respectively (Figure 4 A, B). Neither longer
exposure times, nor higher doses of heparinase could reduce
thickness and stiffness further (Figure 4 A-D). Of note,
digestion of the eGC with heparinase I had no obvious effect
on the following part (cell cortex) of the force separation curve
(Figure S1). Addition of heparin, a natural substrate for
heparinase, completely abolished these changes, excluding
non-enzymatic effects of heparinase treatment (Figure S2). In
addition, we used hyaluronidase and chondroitinase to strip the
eGC of two other, highly abundant components, namely
hyaluronan and chondroitin sulfate. Interestingly,
nanomechanical changes were identical to those seen after
heparinase I treatment, i.e. both, thickness and stiffness
dropped by approximately 50% (428 ± 105 nm to 209 ± 48 nm
for hyaluronidase and 201 ± 36 nm for chondroitinase, both
P<0.0001) and 35% (0.32 ± 0.02 pN/nm to 0.21 ± 0.03 pN/nm
for hyaluronidase and 0.22 ± 0.03 pN/nm for chondroitinase,
P<0.0001) (Figure 4 E, F). In line with previous in vivo data
[39], the combination of heparinase, hyaluronidase and
chondroitinase reduced thickness and stiffness even more
effectively than the individual enzymes (Figure S3). All of the
above mentioned results were highly reproducible. In summary,
this data indicates that enzymatic removal of any eGC
constituents alters its nanomechanics in a relatively rapid and
uniform fashion.
Proof of principle that the endothelial surface layer
detected by AFM is the eGC
To show that the indentation measurements indeed are able
to disclose the eGC, we performed AFM and electron
microscopy in a paired animal study. To avoid any fixation-bias
(poor results with immersion-perfusion in vitro or after lengthier
Figure 3.  Original force indentation tracings before (A, C) and after (B, C) heparinase I treatment measured on ex vivo rat
aortic samples by AFM.  (A, B) “Overview mode” showing 7 force indentation curves recorded from a single endothelial cell before
and after heparinase I treatment, respectively. (C) Each force indentation curve was then analyzed separately using a higher
magnification (“working mode”) which facilitates the determination of the thickness and the stiffness of the endothelial glycocalyx by
linear approximation. Please note that values on X- and Y-axis in A and B are approximations for graphical illustration.
doi: 10.1371/journal.pone.0080905.g003
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Figure 4.  Time- and dose-dependent effects of enzyme digestion on eGC thickness and stiffness.  Enzymatic removal of
heparan sulfate residues by heparinase I in vitro led to a time- and dose-dependent reduction of eGC thickness (A, C) and stiffness
(B, D) on freshly-isolated rat aorta preparations. Similar results were obtained using hyaluronidase and chondroitinase (E, F) to strip
the eGC of hyaluronan and chondroitin sulfate, respectively. Data shown are from independent AFM experiments using paired aorta
preparations derived from two rat aortas (indicated by either green or blue dots). Each dot represents an average of ≥5 force
indentation curves per tip-position (i.e. per individual endothelial cell). *P<0.0001 versus untreated; #P<0.01 vs. 15 min, or solvent,
or 0.1 S-U/mL chondroitinase, respectively; ‡P<0.001 vs. 0.1 Sigma Units/mL heparinase I; †P<0.0001 vs. 0.5 Sigma Units/mL
heparinase I; ns, not significant. Horizontal bars indicate mean values.
doi: 10.1371/journal.pone.0080905.g004
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interruption of blood flow [14]), aortas were perfusion-fixed in
situ (the gold standard for imaging the eGC structure). Electron
microscopy revealed a homogenous and well-preserved
glycocalyx on aortic endothelium from solvent-treated rats.
Forty-five minutes after injection of heparinase in vivo, thinning
and loss of filaments of the endothelial glycocalyx as observed
by electron microscopy was paralleled by a reduction in
thickness and stiffness, respectively (Figure 5). Taken together,
the data provides further evidence, that the heparinase-
sensitive endothelial surface layer, disclosed by AFM
measurements, is indeed the eGC.
Deterioration of the eGC during murine endotoxemia
Several lines of evidence suggest that endotoxin-induced
inflammatory reactions lead to perturbation of the endothelial
glycocalyx [40-42]. We therefore asked whether our AFM
nanoindentation protocol can depict endothelial glycocalyx
deterioration during murine endotoxemia. After having
excluded differences in terms of thickness and stiffness
between untreated mice and rats (Figure S4), adult mice were
injected i.p. with a relatively low dose of LPS (1 mg/kg BW) or
vehicle. After 18 h, aortas were harvested and immediately
analyzed for endothelial glycocalyx by AFM. Indeed, AFM
reliably detected a marked reduction in glycocalyx thickness
(266 ± 17 vs. 137 ± 16 nm, P<0.0001) and stiffness (0.34 ±
0.03 vs. 0.21 ± 0.01 pN/mn, P<0.001) in LPS challenged mice
compared to solvent treated controls (Figure 6 A, B).
Sepsis mediators reduce glycocalyx thickness in vitro
Having observed this effect of LPS in vivo, we next tested
whether LPS alone could reproduce glycocalyx deterioration in
vitro. Using the identical AFM-protocol as with aorta
Figure 5.  Proof of principle that the endothelial surface layer detected by AFM is the eGC.  Enzymatic degradation of the
eGC in vivo was induced by infusing healthy rats with heparinase I or solvent (n=5 per group, indicated by different color/shape).
After 45 min aortas were harvested for transmission electron microscopy (EM) or AFM analysis, respectively. The heparinase-
induced loss of filaments and thinning of the aortic eGC observed by EM (A, B) corresponded well with the decrease in eGC
thickness detected by AFM (C, D). Each dot refers to a different tip position showing an average value of ≥5 force indentation
curves. For statistical comparison, a single average value per animal was calculated. *P<0.05, **P<0.001. Horizontal bars indicate
mean values.
doi: 10.1371/journal.pone.0080905.g005
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preparations, we first ensured the existence of a fully-
developed, heparinase-responsive eGC on human pulmonary
microvascular endothelial cells (HPMEC) (Figure 6 C, D) as
well as on various other endothelial cell-lines and primary
culture (Figure 7). As expected, treatment with LPS alone
decreased glycocalyx thickness and stiffness on HPMECs by
48% (P<0.0001) and 29% (P< 0.0001), respectively. Similarly,
exposure to either thrombin or TNF-α alone led to a marked
Figure 6.  Damage of the eGC in sepsis.  LPS challenge in vivo led to a decrease in eGC thickness (A) and stiffness (B). Adult
mice were injected with Lipopoly-saccharides (LPS) from E. coli (1 mg/kg BW) or solvent (n=4 per group, indicated by different
color/shape). After 18 h, aortas were harvested and immediately analyzed for eGC by AFM. Each dot refers to a different tip position
showing an average value of ≥5 force indentation curves. For statistical comparison, a single average value per animal was
calculated. *P<0.001.
Treatment with either heparinase I, thrombin, LPS or TNF-α alone for 60 min was sufficient to decreased eGC thickness (C) and
stiffness (D) on human pulmonary microvascular endothelial cells (HPMEC) in vitro. Data are expressed as mean (+/- standard error
of mean) of n=3 samples per treatment condition. The average value per sample was calculated from a total of 25 force indentation
curves, derived from five different tip-positions. *P<0.0001 versus untreated; #P<0.0001 vs. solvent; ns, not significant.
doi: 10.1371/journal.pone.0080905.g006
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reduction of glycocalyx thickness by 48% / 55% (P<0.0001)
and 36% / 35% (P<0.0001), respectively (Figure 6 C, D). In
summary, our data indicate that classical sepsis mediators,
such as LPS, TNF-α, or thrombin alone are sufficient to rapidly
deteriorate the eGC in vitro.
Discussion
Whilst special electron microscopic staining procedures
uncovered that the luminal surface of the endothelium
expressed a carbohydrate layer by the mid-1940s, it was
considered to be without major physiological relevance or
functional significance for a long time. In the past two decades,
however, intravital microscopy studies revealed that the eGC
represents a substantial intravascular compartment
contributing significantly to vascular wall homeostasis [7,43]. In
the present study, we show that AFM can reliably depict
nanomechanics of the eGC on a variety of living endothelial
cells ex vivo and in vitro. Application of this technique in further
experiments showed, that classical sepsis mediators, such as
LPS, TNF-α, or thrombin alone are sufficient to rapidly
deteriorate the eGC, as observed during murine endotoxemia.
Previous studies have reported a wide range of thickness
values of the glycocalyx layer. This is partly due to different
species and types of blood vessels used in experiments, and
partly due to heterogeneous visualization methods employed.
For example Gao and Lipowsky [39] detected an average eGC
thickness of 463 nm in post-capillary venules of the intestinal
mesentery of the rat using intravital microscopy to measure the
exclusion zones for blood cells as opposed to fluorescent
tracers. Berg et al. [19] could show by electron microscopy,
that the rat myocardial capillary endothelial surface is coated
with a 200 to 500 nm-thick carbohydrate layer. Using intravital
fluorescent micro-particle image velocimetry in mouse
cremaster muscle venules, Potter and Damiano detected a
hydrodynamically relevant glycocalyx thickness of 520 nm [44].
In contrast to those impressive in vivo data, glycocalyx
thickness on cultured endothelial cells has been found to be on
the order of tens: By electron microscopy, Chappell et al. [14]
found a glycocalyx thickness ranging from only 29 to 118 nm
on primary HUVECs, whereas perfusion-fixed umbilical vein
glycocalyx measured 878 nm. A similar discrepancy was found
by Potter and Damiano [44], who detected a hydrodynamically
relevant glycocalyx thickness of less than 30 nm on HUVECs
cultivated in perfused microchannels. Based on these findings,
it has been a matter of debate if this discrepancy is due to
methodological limitations, or if culturing conditions impede the
assembly of a mature eGC in vitro [45].
In contrast to those previous reports, our AFM data provides
evidence for the existence of a mature, enzyme-sensitive
endothelial glycoclayx on both, freshly isolated rat/mouse aorta
preparations and cultured endothelial cells by a linear
approximation over the first hundreds of nanometers of the
force indentation curves that represent the eGC. In contrast to
the epithelial surface layer (entropic brush model) [26,28], the
eGC is neither a stiff nor a homogeneous structure due to
various electrostatic and molecular interactions between its
constituents. The average nanomechanical thickness of the
glycocalyx was 250 - 350 nm on ex vivo aortic preparations
from mice and rats, respectively. Although heterogeneity and
Figure 7.  AFM measurements in various types of living endothelial cells in vitro.  AFM nanoindentation measurements in
various types of living endothelial cells in vitro, exposed to solvent or heparinase for 60 min. Enzymatic removal of heparan sulfate
residues by heparinase I reduced eGC thickness (A) and stiffness (B) on confluent monolayers of human umbilical vein endothelial
cells (HUVEC), immortalized human umbilical vein cells (EA.hy926), human pulmonal microvascular endothelial cells (HPMEC,
clone ST1.6R), murine brain microvascular cells (bEnd.5), and bovine aortic endothelial cells (GM7373). Data are expressed as
mean (+/- standard error of mean) of n=3 samples per treatment condition. The average value per sample was calculated from a
total of ≥25 force indentation curves, derived from 15 different tip-positions. *P<0.0001.
doi: 10.1371/journal.pone.0080905.g007
Glycocalyx in Sepsis
PLOS ONE | www.plosone.org 10 November 2013 | Volume 8 | Issue 11 | e80905
limitations of in vivo visualization methods probably impede any
direct comparison of glycocalyx dimensions, we noted that this
value was compatible with many of the aforementioned reports
[19,39,44]. A possible explanation for the unexpected
abundance of the glycocalyx seen in vitro is that we examined
glycocalyx dimensions directly (i.e. physically) without exposing
cultured endothelial cells to potentially harmful fixation or
staining procedures, thereby avoiding impairment of the fragile
glycocalyx structure. Moreover, it is important to know that the
thickness of the eGC in vivo is not homogeneous and varies
even within a single vessel, probably due to disturbed laminar
blood flow [46].
When different types of endothelial cells were compared in
vitro, we found quite similar glycocalyx nanomechanics
regardless of vessel diameter (microvascular vs.
macrovascular), culture conditions (primary culture vs.
immortalized cell lines), vascular bed (aorta vs. brain vs. lung
vs. umbilical cord), or species (human vs. rodent vs. bovine
endothelial cells). This finding is surprising, given that
glycocalyx dimensions of the macrocirculation presumably
exceed those of the microcirculation, at least in vivo [15,47,48].
However, only recently, Bai et al found a 300 nm to 1µm thick
enzyme-sensitive glycocalyx on cultured HUVECs by confocal
microscopy [49]. From a technical perspective it is possible that
our AFM approach can detect thickness and stiffness only in
more dense glycocalyx-layers close to the plasma membrane
[7,39], thereby underestimating (cell type specific)
heterogeneity of the looser outer regions of the eGC. Another
explanation could be that the absence of fluid shear stress
and/or reduced abundance of plasma proteins may result in
partial collapse of the glycocalyx during the AFM procedure. In
the future, we will try to perform nanoindentation
measurements under flowing conditions with various albumin
concentrations to address these aspects further.
Glycocalyx research has traditionally focused on thickness
as a surrogate of structural integrity. Although highly intuitive in
principle, this concept provides no conclusions concerning the
mechanical properties of this highly elute and deformable layer.
Any change of the glycocalyx composition, for example by
enzymatic digestion, has the potential to affect the way by
which loading forces are transmitted to the underlying
membrane and cytoskeleton [32]. It is reasonable to assume
that glycocalyx stiffness is a surrogate of both, hydration and
packing density of the glycocalyx. Using heparinase as a
degrading enzyme, we have previously shown that the eGC
stiffness correlates strongly with the amount of stained heparan
sulfate residues [31]. Interestingly, here we could show that
enzymatic removal of any of its main constituents caused
considerable softening of the glycocalyx, which exemplifies the
importance of considering the synergetic interaction of all
glycocalyx constituents as a whole.
Glycocalyx stiffness in the current study was slightly higher
than in previous nanoindentation experiments performed on
split-open arteries obtained from a human umbilical cord [29].
This difference appears likely due to different settings and
samples used in the experiments. Only recently, O'Callaghan
[50] and Bai [49] used nanoindentation to determine the
Young's modulus (=elastic stress) of the glycocalyx on bovine
lung microvascular endothelial cells (0.26 kPa) and HUVECs
(0.39 kPa), respectively. The mathematical model (Hertz
contact theory) used to calculate the Young's modulus
approximates that the indented material is isotropic,
frictionless, non-conforming, and continuous. This assumption,
however, does not account for the very complex nonlinear
anisotropic multilayer structure of the eGC. Furthermore, the
Hertz model provides different values for stiffness caused by
various boundary conditions. Due to the variety of boundary
conditions the Hertz contact theory is probably not adequate for
describing nanomechanical properties of the eGC. Thus, the
Young's modulus cannot be compared with stiffness, as
derived by our simplified model of a linear fit.
In sepsis, the glycocalyx has been generally understudied, in
part because of the aberrancy of in vitro preparations and its
putative degradation during tissue handling [51]. Experimental
studies in rats [40], pigs [41], and humans [42] have shown that
LPS administration induces a significant rise in circulating
glycocalyx constituents, such as heparan sulfate and
syndecan-1. In addition, TNF-α has been shown to induce
glycocalyx shedding in a hamster cremaster [52] and isolated
guinea pig heart model [4]. Only recently, a groundbreaking
intra-vital microscopy study by Schmidt et al. [53] provided
compelling evidence, that LPS-induced vascular
hyperpermeability and leukocyte adhesion in murine lungs is
initiated by TNF-α-dependent degradation of the pulmonary
endothelial glycocalyx [53]. However, complex in vivo imaging
studies usually preclude rapid and economic identification of
underlying molecular mechanisms. Here we used a novel AFM-
based protocol to analyze deterioration of the eGC in the
context of experimental sepsis. In accordance with the above
mentioned reports we could depict severe glycocalyx damage
in response to LPS-treatment in vivo. Of note, in vivo effects of
LPS were essentially reproducible on HPMECs in vitro,
demonstrating that glycocalyx damage in response to LPS
does not require additional (non-endothelial) effector cells.
Nanomechanical changes induced by TNF-α and thrombin,
respectively, were identical to those seen after LPS exposure,
suggesting that glycocalyx deterioration is not confined to
endotoxemia, but probably occurs across the whole spectrum
of critical illness. Consistent with this notion, increased plasma
levels of shed glycocalyx constituents have been reported in
patients with major trauma [54], acute lung injury [53], and after
major vascular surgery with global or regional ischemia [55,56].
Some limitations regarding our study need to be addressed.
First of all the eGC slope of the force separation curve may
partially contain simultaneous deformation of the plasma
membrane and the underlying cortical actin web (cell cortex).
At least heparinase I did not affect cortical stiffness of the cell
per se. Of course it would be very interesting to analyze the
eGC alone (i.e. without the cell cortex). However, we are not
aware of an experimental setup which would enable us to
address this aspect further. Second, in contrast to a sharp AFM
tip, the spherical tip used in this study is incapable of
penetrating the eGC, but it is able to compress this surface
structure to a maximum extent. Due to the fact that the eGC is
a well compressible structure, it is important to mention, that
the AFM approach of this study gives an indication of the
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apparent thickness, rather than the true anatomical thickness
of the eGC. Finally, we cannot exclude, that a possible change
of the cortical stiffness in response to inflammatory mediators
might have influence thickness and stiffness of the glycocalyx.
However, preliminary experiments have shown that softening
of the cell cortex does not change the measured thickness and
stiffness of the eGC.
Conclusion
Our findings suggest that AFM might serve as a novel tool to
investigate glycocalyx pathobiology in cultured endothelial
cells. This approach not only allows the quantification of
thickness but also opens up a mechanical dimension (stiffness)
for the investigation of glycocalyx damage in experimental
sepsis. Understanding deterioration and refurbishment of the
eGC in the context of sepsis will be pivotal in order to develop
therapeutic strategies against vascular leakage and eventually
improve outcome critically-ill patients.
Supporting Information
Figure S1.  Effect of heparinase on cortical stiffness.
Treatment with heparinase I (1.0 S-U/mL, 60 min) in vitro has
no significant effect on the stiffness of the plasma membrane
and the underlying cortical actin web (cell cortex) on freshly-
isolated rat aorta preparations. Data shown are from
independent AFM experiments using paired aorta preparations
derived from two rat aortas (indicated by either green or blue
dots). Each dot represents an average of ≥5 force indentation
curves per tip-position (i.e. per individual endothelial cell). ns,
not significant. Horizontal bars indicate mean values.
(EPS)
Figure S2.  Inhibition of heparinase by heparin in vitro. The
decrease of eGC thickness and stiffness after incubation with
heparinase I for 60 min is completely abolished by addition of
heparin, a natural substrate for heparinase I. Data shown are
from independent AFM experiments using paired aorta
preparations from three rat aortas (indicated by color/shape).
Each dot represents an average of ≥5 force indentation curves
per tip-position (i.e. per individual endothelial cell). *P<0.0001
versus untreated; #P<0.0001 vs. heparin; ‡P<0.0001 vs.
heparin plus heparinase. Horizontal bars indicate mean values.
(EPS)
Figure S3.  Effect of enzyme mix on glycocalyx properties.
The decrease of eGC thickness and stiffness after incubation
with the combination of heparinase, hyaluronidase and
chondroitinase for 60 min reduced thickness and stiffness even
more effectively than the individual enzymes. Data shown are
from independent AFM experiments using paired aorta
preparations (indicated by color/shape). Each dot represents
an average of ≥5 force indentation curves per tip-position (i.e.
per individual endothelial cell). *P<0.0001 versus buffer;
#P<0.0001 vs. heparinase; ‡P<0.05 vs. chondroitinase,
†P<0.001 vs. hyaluronidase. Horizontal bars indicate mean
values.
(EPS)
Figure S4.  Comparison of rat and mouse aorta. Enzymatic
removal of heparan sulfate residues by heparinase I reduced
eGC thickness (A) and stiffness (B) on aorta preparations from
rats or mice, respectively. Data shown are from independent
AFM experiments using paired aorta preparations from three
aortas per species. Each bar represents an average of 5 force
indentation curves per tip-position (i.e. per individual
endothelial cell) and in summary five tip-positions per aorta
patch (= 15 values per bar). *P<0.0001.
(EPS)
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